SEARCH

SEARCH BY CITATION

References

  • 1
    Hippe E, Clausen NA, Gimsing P, Haedersdal C. Resistant multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP-regime). Eur J Haematol 1987;39: 8889.
  • 2
    Wislöff F, Andersen P, Andersson TR, Brandt E, Eika C, Fjaestad K, Ly B, Lovasen K, Strom BR, Tjonnfjord GE. Has the incidence of multiple myeloma in old age been underestimated? The Myeloma Project of Health Region I in Norway. Eur J Haematol 1991;47: 333337.
  • 3
    Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. Br J Haematol 1990;74: 185191.
  • 4
    Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I – a randomised study. Myeloma Group of Western Sweden. Eur J Haematol 1993;50: 95102.
  • 5
    Gimsing P, Bjerrum OW, Brandt E, et al. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regime): a phase II study. The Nordic Myeloma Study Group (NMSG). Brit J Haematol 1991;77: 7379.
  • 6
    Wislöff F, Gimsing P, Hedenus M, Hippe E, Palva I, Talstad I, Turesson I, Westin J. Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG). Eur J Haematol 1992;48: 7074.
  • 7
    Keldsen N, Bjerrum OW, Dahl IM, Drivsholm A, Ellegaard J, Gadeberg O, Gimsing P, Grovold T, Hansen MM, Hippe E. Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP-regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group. Eur J Haematol 1993;51: 8085.
  • 8
    Ahre A, Bjorkholm M, Mellstedt H, et al. Human leukocyte interferon and intermittent high dose melphalan-prednisone administration in the treatment of myeloma: a randomised clinical trial from the Myeloma Group of Central Sweden. Treat Rep 1984;68: 13311338.
  • 9
    Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322: 14301434.
  • 10
    Westin J, Rödjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomised study. Cooperative Study Group. Br J Haematol 1995;89: 561568.
  • 11
    Turesson I, Zetterwall O, Cuzick J, Waldenström JG, Velez R. Comparison of trends in the incidence of multiple myeloma in Malmo, Sweden and other countries, 1950–1979. N Engl J Med 1984;310: 421424.
  • 12
    Hjorth M, Holmberg E, Rodjer S, Westin J. Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. The Myeloma Group of Western Sweden. Br J Haematol 1992;80: 5561.
  • 13
    Hjorth M, Westin J, Dahl IM, et al. Interferon-alpha2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann Intern Med 1996;124: 212222.
  • 14
    Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95: 711.
  • 15
    Hjorth M, Holmberg E, Rödjer S, Taube A, Westin J. Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centres. Br J Haematol 1995;91: 109115.
  • 16
    Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334: 488493.
  • 17
    Wislöff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996;92: 604613.
  • 18
    Wislöff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: Results of a Nordic randomised trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol 1996;94: 324332.
  • 19
    Nord E, Wisloff F, Hjorth M, Westin J. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial. Pharmacoeconomics 1997;12: 89103.
  • 20
    Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J. and the Nordic Myeloma Study Group. Cost-utility analysis of high-dose melphalan with autologous stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol 2001;66: 328336.
  • 21
    Hjorth M, Holmberg E, Rodjer S, Taube A, Westin J. Physicians’ attitudes toward clinical trials and their relationship to patient accrual in a Nordic multicenter study on myeloma. Control Clin Trials 1996;17: 372386.
  • 22
    Turesson I, Abildgaard N, Ahlgren T, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 1999;106: 10051012.
  • 23
    Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma – a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994;53: 207212.
  • 24
    Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000;65: 175181.
  • 25
    Dahl IM, Turesson I, Holmberg E, Lilja K. Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood 1999;93: 41444148.
  • 26
    Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998;91: 806812.
  • 27
    Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000;95: 388392.
  • 28
    Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone lesions. Blood 2001;98: 22692271.
  • 29
    Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Waage A, Seidel C. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002;100: 39253929.
  • 30
    Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group. Br J Haematol 1997;96: 103110.
  • 31
    Johnsen HE. Report from a Nordic workshop on CD34+ cell analysis: technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories. J Hematother 1995;4: 2128.
  • 32
    Johnsen HE, Knudsen LM. Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: report from the second Nordic workshop. Nordic Stem Cell Laboratory Group (NSCL-G). J Hematother 1996;5: 237245.
  • 33
    Johnsen HE, Baech J, Nikolajsen K. Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: report from the third workshop. Nordic Stem Cell Laboratory Group. J Hematother 1999;8: 1528.
  • 34
    Kaasa S, Hjermstad MJ, Jordhoy MS, Wisloff F, Loge JH. Compliance in quality of life data: a Norwegian experience. Stat Med 1998;17: 623632.
  • 35
    Ringdal K, Ringdal GI, Kaasa S, Bjordal K, Wisloff F, Sundstrom S, Hjermstad MJ. Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken scaling model. Qual Life Res 1999;8: 2543.
  • 36
    Stead ML, Brown JM, Velikova G, Kaasa S, Wisloff F, Child JA, Hippe E, Hjorth M, Sezer O, Selby P. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol 1999;104: 605611.
  • 37
    Miller A, Petrie J. Development of practice guidelines. Lancet 2000;355: 8283.
  • 38
    Zurlo A, Therasse P. Addressing the challenge of intergroup studies in oncology: the EORTC experience. European Organization for Research and Treatment of Cancer. Eur J Cancer 2002;38(Suppl. 4):6972.
  • 39
    Ohno R. Cooperative oncology groups in Japan: experience from the Japan Adult Leukemia Study Group. Cancer Chemother Pharmacol 1998;42(Suppl.):S93S97.
  • 40
    Gridelli C, Daniele B. Originality, benefits and difficulties of clinical research performed by cooperative groups: the experience of an Italian lung cancer study group. Crit Rev Oncol Hematol 1999;8: 1528.
  • 41
    Rödjer S, Nilsson B, Westin J. for the Nordic Myeloma Study Group. Do anthracyclines have a role in the therapy of multiple myeloma? Hypothesis and debate. Hematol J 2000;1: 422426.
  • 42
    Lenhoff S, Hjorth M, Gimsing P., Tangen JM, Westin J. Impact of age on survival after intensive therapy in newly diagnosed multiple myeloma. The Nordic Myeloma Study Group (NMSG). American Society of Hematology, 46th Annual Meeting, 2004: Abstract 924.
  • 43
    Waage A, Turesson I, Juliusson G, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004;125: 149155.